Aubrey S. Okpaku, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 10 Cordage Park Cir Ste 227, Plymouth, MA 02360 Phone: 508-830-6991 Fax: 508-830-6993 |
News Archive
A new type of drug originally developed for lung cancer can reduce the size of breast cancer tumours when taken in combination with other drugs.
Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference "Tolerance and Autoimmunity" being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled "IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates" was made by Idera scientists.
An unprecedented molecular view of the critical early events in gene expression, a process essential for all life, has been provided by researchers at Georgia State University, the University of California at Berkeley and Northwestern University.
WBTshowcase is pleased to announce the selection of Penman PR as the organization's public relations representative for WBT2010. WBTshowcase is the world's largest forum offering a prescreened, pre-prepped collection of undiscovered companies and intellectual property emanating from top universities, labs and research institutions from across the country.
› Verified 2 days ago